DOCSLIB.ORG

United States (12) Patent Application Publication Oo) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States (12) Patent Application Publication Oo) Pub US 20070134261A1 US 20070134261A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2007/0134261 A l Hancock et al. (43 ) Pub. Date: Jun. 14,2007 (54) EFFECTORS OF INNATE IMMUNITY which is a continuation-in-part of application No. 10/308,905, filed on Dec. 2, 2002. (76) Inventors: Robert E.W. Hancock, Vancouver (CA); B. Brett Finlay,Richmond (CA); (60) Provisional application No. 60/336,632, filed on Dec. Monisha Gough Scott, Portland, OR 3, 2001. (US); Dawn Bowdish, Marston (GB); Carrie Melissa Rosenberger, Seattle, Publication Classification WA (US); Jon-Paul Steven Powers, Vancouver (CA); Jie Yu, Vancouver (51) Int. Cl. (CA); Neeloffer Mookherjee, A61K 39/02 (2006.01) Vancouver (CA) C12Q 1/68 (2006.01) (52) U.S. Cl........................... 424/185.1; 435/6; 424/234.1 Correspondence Address: DFA PIPER US FFP (57) ABSTRACT 4365 EXECUTIVE DRIVE The present invention provides a method of identifying SUITE 1100 agents that enhance innate immunity in a subject. The SAN DIEGO, CA 92121-2133 (US) invention further provides a method of selectively supress- (21) Appl. No.: 11/400,411 ing sepsis by suppressing expression of a proinflammatory gene while maintaining expression of an anti-inflammatory (22) Filed: Apr. 7, 2006 gene. Also provided are methods of identifying a polynucle­ otide or pattern of polynucleotides regulated by one or more Related U.S. Application Data sepsis or inflammatory inducing agents and inhibited by a peptide is described, methods of identifying a pattern of (63) Continuation-in-part of application No. 11/241,882, polynucleotide expression for inhibition of an inflammatory filed on Sep. 29, 2005, which is a continuation-in-part or septic response, and compounds and agents identified by of application No. 10/661,471, filed on Sep. 12, 2003, the methods of the invention. Patent Application Publication Jun. 14, 2007 Sheet I of 22 US 2007/0134261 A l 25000 20000 15000 1000 0 - Average Average CFU/ral 5000 - 2.5 mg/kg 10 mg/kg S. aureus 0.1 mg/kg SEQ ID NO: 7 SEQ ID NO: 7 0.1 mg/kg Cefepime + 2.5 Cefepime + + S. aureus + S. aureus mg/kg SEQ ID NO: 7 S. aureus + S. aureus Treatment Group - Concentration FIG. I Patent Application Publication Jun. 14, 2007 Sheet 2 of 22 US 2007/0134261 A l Pqitide ERK-P Jl-actin FIG. 2A ERK-P SOOO 0 KAnIpqrtiA 1Ie1WjFCS 4000 Intensity 50 KAnlpqrtide.Iim FCS 3000 2000 1000 0 Donortfl Donorffi Donorffi FIG. 2B P38-P O KAnlpq7AA l IOV j FCS Intensity 50 KAnlpqitiA. 10¾¾ FCS Dourfl Dcncr #2 Oconeiffi FIG. 2C Patent Application Publication Jun. 14, 2007 Sheet 3 of 22 US 2007/0134261 A l 80000 70000 +10% FCS 60000 Serum free 50000 LLJZ ^ g /m l LL-37 40000 150 μς/ΓΠΐ LL-37 Intensity 30000 20000 10000 serum free 10% FCS 10% HS FIG. 3 Patent Application Publication Jun. 14, 2007 Sheet 4 of 22 US 2007/0134261 A l 50000 40000 30000 (ϋ Donor 1 ■ Donor 2 20000 10000 50 50 50 50 DC m edia FCS IL-4 GM-CSF only 100ng/ml 100ng/ml FIG. 4 Patent Application Publication Jun. 14, 2007 Sheet 5 of 22 US 2007/0134261 A l 1000 I 800 600 0 pg/ml SEQ ID NO: 1 IL-8 IL-8 pg/ml 400 50pg/ml SEQ ID NO: 1 200 apical basolateral FIG.5A Vi "ω a XJ ω TO φ t"· CO I to(I) TO s? O C 35 O U- I MCP-1 IL-6 IL-8 MCP-3 FIG. 5B Patent Application Publication Jun. 14, 2007 Sheet 6 of 22 US 2007/0134261 Al B 2-5 2 η ZO 1.5 1 -I 0.5 0 0.0 0 0.5 1 2 5 10 20 50 LL-37 μς/πιΙ cP FIG. 6A FIG. 6B 3.5 -I 3 g 250 E 2.5 'W'C 2 a b. 1.5 Z 1 Z 100 H 0.5 ■ C L FIG. 6C FIG. 6D Patent Application Publication Jun. 14,2007 Sheet 7 of 22 US 2007/0134261 A l 0.8 0.6 0.8 - 0.4 0.6 0.4 TNF-α TNF-α (ng/ml)0.2 - 0.2 I 2 4 24 hr 1 2 4 24 h r FIG. 7A FIG. 7B % Inhibition of TNF-a 1 hr 2 hr 4 hr 24 hr A Simultaneous 90 95 97 97 B Delayed 15 54 58 80 C Pre-treatment 64 35 35 24 0.8 0.6 0.4 1 2 4 24 h r FIG. IC Patent Application Publication Jun. 14, 2007 Sheet 8 of 22 US 2007/0134261 A l 3.0 Ί i r i r 1.2 LPS LTA 2.0 0.8 JXL 0.4 1.0 0.0 0.0 12η 18η LPS LTA 1 2 0.6| Control CpG 0.8 0.4 24 24 hr 4 hr 0.4 Concentration (ng/ml) 0.2 0.0 L 0.0 LL TNF-α N/A IL-ip IL-6 IL-8 TNF-a IL-Ιβ IL-6 IL-8 TNF-a FIG. 8 Patent Application Publication Jun. 14, 2007 Sheet 9 of 22 US 2007/0134261 A l 1 hr 2 hr 4hr 24 hr S n ' + LPS m m m OiftjTf0 + LPS + LL-37 FIG. 9A + LPS 24 W fy ri O '■M <0 O) O 7 ΝΡ-κΒ-related genes 5 NF-icB-related genes 4 NF-xB-related genes I I 24 1 24 1 O ε OCD —I 11 NF-ieB-rolated genes 1 2 4 24 No. DE Total No. NF-κΒ Targets Genes No. clusters Clusters with NF k B targets BIRC2, CD80, IL6, KRT3, PTAFR1 LPS 561 15 3 BIRC3, CCL2T CD44, CD83. CFLAR, CXCL2,IER3, ILIA, NFKBIA, NFKBI, RELB, PTGS2,TNF1 TNFAIP2, TNFAIP3, FUCAl LPS + BCL2A1. BIRC3, CCL3, CCLI9, LL-37 410 S 2 CCL2, CXCL2, IER3, NFKBIA, RELB, SOD2, TNFAIP3, TRAFl FIG. 9B Patent Application Publication Jun. 14, 2007 Sheet 10 of 22 US 2007/0134261 A l 10 RELB 1 100 1,000 100 TNFAIP2 IL-10 100 100 1,000 100 IL-8 1CXCLI 100 Relative Relative fold change 100 100 TNIP3 100 NFKBIAi 10 1 2 4 24 hr 1 2 4 24 hr 1 2 4 24 hr FIG. 10 Patent Application Publication Jun. 14, 2007 Sheet 11 of 22 US 2007/0134261 A l LL-37 RELB cREL FIG. IlA neg cells + LL-37+ LPS + LPS + LPS + LL37 + Inh FIG. IlB Patent Application Publication Jun. 14, 2007 Sheet 12 of 22 US 2007/0134261 Al LL-37 TNF-a LL-37 TLR-4 Membrane m lL lL MyD88 B-4A TRAM MAPK IRAK LL-37 TRAF Ιν Ν Λ Λ Λ Λ Nucleus Deeradation I TNF-α I INFAIP2 1 ► I-------- — ► NFk BIA ---- TNFAIP3 I NFkBIA ELK-I & other TFs FIG. 12 Patent Application Publication Jun. 14, 2007 Sheet 13 of 22 US 2007/0134261 A l fCtORA · * > : ISTAT31 I du^ed paliMay; FIG. 13 Patent Application Publication Jun. 14, 2007 Sheet 14 of 22 US 2007/0134261 A l N1N2N3N* N1N2N3N4 Relative Relative Fold Change Ni he re Nt mrcrcm N1N2N3N4 Bdogjcal replicates: Monocytes isdatedfrom fdr incfvidual donors FIG. 14 Patent Application Publication Jun. 14, 2007 Sheet 15 of 22 US 2007/0134261 Al C l] Control ■ SEQ 7 NI N2 N3 N4 NI N2 N3 N4 Biological replicates: Tissue culture supernatants from PBMC of four individual donors FIG. 15 Relative Relative Fold Change (pg/ml)IL-6 NI N2 N3 N4 N1N2N3N4 N I h C W M Biological replicates: MonotytesisolatBdftqTifourincividuaI donors FIG. 16 Patent Application Publication Jun. 14, 2007 Sheet 16 of 22 US 2007/0134261 A l ■ LPS (2 ng/ml) P LPS + SEQ 7 J NI N2 N3 Biological replicates: Tissue culture supernatants from PBMC of three individual donors FIG. 17A B 900 -| 800 £ 700 Ui 600 a 500 a 400 U- 300 Z I- 200 100 0 Untreated LPS SEQ 7 LPS+SEQ 7 FIG. 17B Patent Application Publication Jun. 14, 2007 Sheet 17 of 22 US 2007/0134261 A l Total DE genes: 681 LL37 ^59719 SEQ ID NO: 7 DE and DE and m statistically statistically significant gene v^gnificant genes FIG. 18 Total-ΙκΒ α GAPDH 0 0.5 I 2 3 6 h LL-37 FIG. 19 Patent Application Publication Jun. 14, 2007 Sheet 18 of 22 US 2007/0134261 A l IL-6 release from PBMCs 2000 1600 1200 800 IL-6 IL-6 (pg/ml) 400 0 .Z f * V ΛΓ vV. * v VP sV VvV FIG. 20A MCP-3 release from PBMCs —1200 1900 Q « 600 I O 300 § 0 V o sV nV V FIG. 20B Patent Application Publication Jun. 14, 2007 Sheet 19 of 22 US 2007/0134261 A l P B M C s ΐ3 & β φ ρ-ΙκΒα (41 kDa) GAPDH (36kDa) C trl IL-1 β LL-37 comb C trl IL-1 β LL-37 com b FIG. 21A Ctrl IL-1 β LL-37 comb ctrl IL-1 P LL-37 comb I 2 *. * * 'I V ·-‘ I" p50/105 ν ύ& ά β ίφ * fi Λ ei^ 5tV i "eT THP-1 cells f* * * .··:■■ · . · '1T:. ■>··■.'. .··?', »7>·|'.;··· :· .V'j*· .·· *u I ·-..■· *·■·. ·· ' .·: \ · ; v .V. , ., · · . λ. ^ P50/105 Human PBMCs C trl IL-Ip LL-37 comb ctrl IL-1 P LL-37 comb 30 60 FIG. 21B Patent Application Publication Jun. 14, 2007 Sheet 20 of 22 US 2007/0134261 A l 0 -LY294002 MCP-3 production in PBMCs 1 +LY294002 1200 800 MCP-3 (p g/m400 l) * \V V «vV λ* FIG.
Load more

Recommended publications
  • Integrated Bioinformatic Analysis of RNA Binding Proteins in Hepatocellular Carcinoma
    www.aging-us.com AGING 2021, Vol. 13, No. 2 Research Paper Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma Ling Wang1,*, Zhen Zhang2,3,*, Yuan Li1, Yanyan Wan1, Baocai Xing1,& 1Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital and Institute, Beijing 100142, China 2Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing 100044, China 3Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People’s Hospital, Beijing 100044, China *Equal contribution Correspondence to: Baocai Xing; email: [email protected] Keywords: RNA binding protein, hepatocellular carcinoma, biomarker, transcriptomics, proteomics Received: June 8, 2020 Accepted: November 3, 2020 Published: December 19, 2020 Copyright: © 2020 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT RNA binding proteins (RBPs) are aberrantly expressed in a tissue-specific manner across many tumors. These proteins, which play a vital role in post-transcriptional gene regulation, are involved in RNA splicing, maturation, transport, stability, degradation, and translation. We set out to establish an accurate risk score model based on RBPs to estimate prognosis in hepatocellular carcinoma (HCC). RNA-sequencing data, proteomic data and corresponding clinical information were acquired from the Cancer Genome Atlas database and the Clinical Proteomic Tumor Analysis Consortium database respectively. We identified 406 differentially expressed RBPs between HCC tumor and normal tissues at the transcriptional and protein level.
    [Show full text]
  • Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist
    (19) TZZ _ __T (11) EP 2 192 197 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.06.2010 Bulletin 2010/22 C12Q 1/68 (2006.01) (21) Application number: 08170119.5 (22) Date of filing: 27.11.2008 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Habets, Winand Designated Extension States: Life Science Patents AL BA MK RS PO Box 5096 6130 PB Sittard (NL) (71) Applicant: Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg 1081 HV Amsterdam (NL) (54) Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist (57) The invention relates to methods for predicting a clinical response to a therapy with a soluble TNF antagonist, TNF or a TNF receptor agonist and a kit for use in said methods. EP 2 192 197 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 192 197 A1 Description [0001] The invention relates to methods for predicting a clinical response to a treatment with a soluble TNF antagonist, with TNF or a TNF receptor agonist using expression levels of genes of the Type I INF pathway and a kit for use in said 5 methods. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with a soluble TNF antagonist, TNF or a TNF receptor agonist.
    [Show full text]
  • Rrna Types in Zebrafish Development
    UvA-DARE (Digital Academic Repository) Distinct maternal and somatic rRNA types in zebrafish development Locati, M. Publication date 2017 Document Version Final published version License Other Link to publication Citation for published version (APA): Locati, M. (2017). Distinct maternal and somatic rRNA types in zebrafish development. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:04 Oct 2021 DISTINCT MATERNAL AND SOMATIC rRNA TYPES IN ZEBRAFISH DEVELOPMENT MAURO LOCATI DISTINCT MATERNAL AND SOMATIC rRNA TYPES IN ZEBRAFISH DEVELOPMENT MAURO LOCATI Distinct Maternal and Somatic rRNA Types in Zebrafish Development ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Universiteit van Amsterdam op gezag van de Rector Magnificus prof. dr. ir. K.I.J. Maex ten overstaan van een door het College voor Promoties ingestelde commissie, in het openbaar te verdedigen in de Aula der Universiteit op woensdag 6 december 2017, te 13:00 uur door Mauro Locati geboren te Palermo, Italië Promotiecommissie: Promotor: Prof.
    [Show full text]
  • Intersections Spring Symposium
    INTERSECTIONS SPRING SYMPOSIUM APRIL TH, 8 Last Name First Name Project Title Page Analyzing the Effect of Urbanization on Abboud Bissan Phylogenetic signal in the Species Columba 1 Abouzahra Sharifah Peripheral IV Catheter Sterilization Device 2 Development of a Liquid Crystal Based Electron Adkins Raymond Shower Detector 2 Purification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) Implicated for its Effects on Al Bahrani Zaid Intraocular Pressure 3 A Window into Metabolite Changes of Live Aljawad Yaqeen Bacteria Following Drug Infusion 3 Anderson Emily In-situ Resource Utilization on Mars 4 The Relationship Between Subjective and Objective Language Assessments For Second- Arredondo Kaitlynn Language Learners 4 Atkinson Scott MotionSense Wave: Toucheless Faucet 5 Ayyar Aneeka Hand Tremor Reduction Device 6 Modifying Low-Emissivity Glass for Use with Bailey Jessica Surface Enhanced Raman Spectroscopy 5 Automated Segmentation and Radiomic Characterization of Visceral Fat on Bowel MRIs for Barbur Iulia Crohn's Disease 6 Periodic Liquid Crystal Order: Theory and Barnaby Gavin-Rae Simulations 7 The Role of Dentistry in the U.S. Opioid Epidemic: Basore Makenna A Literature Review 7 Berends Hannah A Leader’s Role in a Nation’s Stability 8 A Study on Daily Cycles in Activity Levels of Bhatia Shireen Coyotes (Canis latrans) 8 Co-creation of an Intervention with African American Older Adults to Manage Stress Blackshire Gabrielle Associated with Self-management of 9 Developing to Developed: Entrepreneurship in Blatt Noah Latin America
    [Show full text]
  • Supplementary Materials
    Supplementary material. S1. Images from automatic imaging reader Cytation™ 1. A, A’, A’’ present the same field of view. Cells migrating from the upper compartment of the inserts are stained with DID (red color), Cell nuclei are stained with DAPI (blue color). A’ and A’’ demonstrate the method of analysis (A’ – nuclei numbering, A’’ – migrating cells numbering), scale bar – 300 µm. ASC BM-MSC Y BM-MSC A mean SEM mean SEM mean SEM CXCL6 2.240 0.727 4.158 0.677 2.149 1.816 CXCL16 4.277 0.248 0.763 0.405 1.130 0.346 CXCL12 -2.855 0.483 -4.528 0.226 -3.616 0.318 SMAD3 -0.511 0.191 -1.522 0.188 -1.332 0.215 TGFB2 3.742 0.533 1.238 0.210 0.990 0.568 COL14A 1.532 0.357 -0.397 0.736 -1.522 0.469 MHX 1.397 0.414 1.145 0.412 0.642 0.613 SCX 2.984 0.301 2.062 0.320 2.031 0.249 RUNX2 3.290 0.359 2.319 0.388 2.546 0.529 PPRAG 1.720 0.303 2.926 0.423 2.912 0.215 Supplementary material S3. The table provides the mean Δct and SEM values for all genes and all groups analyzed in this study (n=8 in each group). Supplementary material S2. The table provides the list of genes which displayed significantly different expression between hASCs and hBM-MSCs A based on microarray nr Exp p-value Exp Fold Change ID Symbol Entrez Gene Name 1 2.84E-05 16.896 16960355 TM4SF1 transmembrane 4 L six family member 1 2 9.10E-09 12.238 16684080 IFI6 interferon alpha inducible protein 6 3 3.93E-08 11.851 16667702 VCAM1 vascular cell adhesion molecule 1 4 1.54E-05 9.944 16840113 CXCL16 C-X-C motif chemokine ligand 16 5 2.01E-06 9.123 16852463 RAB27B RAB27B, member RAS oncogene
    [Show full text]
  • Identification of Transcriptional Mechanisms Downstream of Nf1 Gene Defeciency in Malignant Peripheral Nerve Sheath Tumors Daochun Sun Wayne State University
    Wayne State University DigitalCommons@WayneState Wayne State University Dissertations 1-1-2012 Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors Daochun Sun Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Recommended Citation Sun, Daochun, "Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors" (2012). Wayne State University Dissertations. Paper 558. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. IDENTIFICATION OF TRANSCRIPTIONAL MECHANISMS DOWNSTREAM OF NF1 GENE DEFECIENCY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS by DAOCHUN SUN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2012 MAJOR: MOLECULAR BIOLOGY AND GENETICS Approved by: _______________________________________ Advisor Date _______________________________________ _______________________________________ _______________________________________ © COPYRIGHT BY DAOCHUN SUN 2012 All Rights Reserved DEDICATION This work is dedicated to my parents and my wife Ze Zheng for their continuous support and understanding during the years of my education. I could not achieve my goal without them. ii ACKNOWLEDGMENTS I would like to express tremendous appreciation to my mentor, Dr. Michael Tainsky. His guidance and encouragement throughout this project made this dissertation come true. I would also like to thank my committee members, Dr. Raymond Mattingly and Dr. John Reiners Jr. for their sustained attention to this project during the monthly NF1 group meetings and committee meetings, Dr.
    [Show full text]
  • Qt38n028mr Nosplash A3e1d84
    ! ""! ACKNOWLEDGEMENTS I dedicate this thesis to my parents who inspired me to become a scientist through invigorating scientific discussions at the dinner table even when I was too young to understand what the hippocampus was. They also prepared me for the ups and downs of science and supported me through all of these experiences. I would like to thank my advisor Dr. Elizabeth Blackburn and my thesis committee members Dr. Eric Verdin, and Dr. Emmanuelle Passegue. Liz created a nurturing and supportive environment for me to explore my own ideas, while at the same time teaching me how to love science, test my questions, and of course provide endless ways to think about telomeres and telomerase. Eric and Emmanuelle both gave specific critical advice about the proper experiments for T cells and both volunteered their lab members for further critical advice. I always felt inspired with a sense of direction after thesis committee meetings. The Blackburn lab is full of smart and dedicated scientists whom I am thankful for their support. Specifically Dr. Shang Li and Dr. Brad Stohr for their stimulating scientific debates and “arguments.” Dr. Jue Lin, Dana Smith, Kyle Lapham, Dr. Tet Matsuguchi, and Kyle Jay for their friendships and discussions about what my data could possibly mean. Dr. Eva Samal for teaching me molecular biology techniques and putting up with my late night lab exercises. Beth Cimini for her expertise with microscopy, FACs, singing, and most of all for being a caring and supportive friend. Finally, I would like to thank Dr. Imke Listerman, my scientific partner for most of the breast cancer experiments.
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: • This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. • A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. • This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. • The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. • When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Regulation and Function of miR-199-3p in Murine and Human Cytomegalovirus Infections Nouf N. M. Laqtom s0898296 A thesis submitted in fulfilment of requirements for the degree of Doctor of Philosophy Division of Pathway Medicine, School of Biomedical Sciences The University of Edinburgh May 2013 Supervisors: Dr. Amy Buck and Dr. Bernadette Dutia i Declaration of Authorship I hereby declare that this thesis is of my own composition, and that it contains no material previously submitted for the award of any other degree. The work reported in this thesis has been executed by myself, except where due acknowledgement is made in the text. Nouf N. M. Laqtom ii Abstract Human Cytomegalovirus (HCMV), the prototypic β-herpesvirus, is the most common cause of congenital infections as well as morbidity and mortality in immunocompromised patients.
    [Show full text]
  • RNA Polymerase I Transcription and Pre-Rrna Processing Are Linked by Specific SSU Processome Components
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press RNA polymerase I transcription and pre-rRNA processing are linked by specific SSU processome components Jennifer E.G. Gallagher,2 David A. Dunbar,3 Sander Granneman,1 Brianna M. Mitchell,3 Yvonne Osheim,4 Ann L. Beyer,4 and Susan J. Baserga1,2,3,5 1Department of Molecular Biophysics and Biochemistry, 2Department of Genetics, and 3Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8024, USA; 4Department of Microbiology, University of Virginia, Charlottesville, Virginia 22904, USA Sequential events in macromolecular biosynthesis are often elegantly coordinated. The small ribosomal subunit (SSU) processome is a large ribonucleoprotein (RNP) required for processing of precursors to the small subunit RNA, the 18S, of the ribosome. We have found that a subcomplex of SSU processome proteins, the t-Utps, is also required for optimal rRNA transcription in vivo in the yeast Saccharomyces cerevisiae.The t-Utps are ribosomal chromatin (r-chromatin)-associated, and they exist in a complex in the absence of the U3 snoRNA. Transcription is required neither for the formation of the subcomplex nor for its r-chromatin association. The t-Utps are associated with the pre-18S rRNAs independent of the presence of the U3 snoRNA. This association may thus represent an early step in the formation of the SSU processome. Our results indicate that rRNA transcription and pre-rRNA processing are coordinated via specific components of the SSU processome. [Keywords: Ribosome; RNA; transcription; RNA processing; SSU processome] Received May 27, 2004; revised version accepted August 19, 2004.
    [Show full text]
  • Mechanism of U18666a-Mediated Cell Death in Cultured Neurons
    MECHANISM OF U18666A-MEDIATED CELL DEATH IN CULTURED NEURONS KOH CHOR HUI VIVIEN (B.Sc.) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF BIOCHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2006 Acknowledgements I would like to thank: My supervisor, Assistant Professor Steve Cheung Nam Sang, for the opportunity to work in his lab and his guidance in this research project. The Biomedical Research Council (BMRC) of the Agency for Science, Technology and Research (A*STAR) of Singapore for the Research Assistant position and financial support (R-183-000-082-305). This work was also financially supported by the National Medical Research Council (NMRC) of Singapore (R-183-000-075-213) and the Academic Research Fund of the National University of Singapore (R-183- 000-060-214). Associate Professor Matthew Whiteman from the Department of Biochemistry for his guidance in oxidative stress studies. Dr. Ou Keli and members of his lab from Agenica Research Pte. Ltd., and Dr. Zhang Dao Hai from the Department of Laboratory Medicine of the National University Hospital for their expertise in proteomics and the use of their facilities. Dr. Li Qiao-Xin from the Department of Pathology of the University of Melbourne for her assistance in Aβ studies; Dr. Qu Dianbo from the Institute of Molecular and Cell Biology for his assistance in radioactive work; Ms Chan Yee Gek from the Department of Anatomy for her assistance in electron microscopy; Jayapal Manikandan from the Department of Physiology for his assistance in GeneSpring™. Ms Seet Sze Jee, Ms Huang Shan Hong and Ms Siau Jialing from the Department of Biochemistry for their technical assistance.
    [Show full text]
  • Solute Carrier Transporters (Slcs) As Possible Drug Targets for Cystic Fibrosis
    UNIVERSIDADE DE LISBOA FACULDADE DE CIÊNCIAS DEPARTAMENTO DE QUÍMICA E BIOQUÍMICA Solute Carrier Transporters (SLCs) as Possible Drug Targets for Cystic Fibrosis Íris Lameiro Petinga Mestrado em Bioquímica Especialização em Bioquímica Médica Dissertação orientada por: Professora Doutora Margarida D. Amaral 2017 Acknowledgments/Agradecimentos Ao concluir este trabalho não posso deixar de agradecer a todas as pessoas que contribuíram de alguma maneira para a sua realização. Em primeiro lugar gostaria de agradecer à professora Margarida Amaral não só por me ter recebido no seu laboratório e grupo de investigação, mas também por toda a orientação e acompanhamento e acima de tudo confiança depositada. Não podia deixar também de agradecer ao professor Carlos Farinha por se ter mostrado sempre disponível para me ajudar, por toda a atenção, paciência e por me ter cativado para a área do estudo da Fibrose Quística desde muito cedo. Agradeço a todos os meus colegas de laboratório que sempre se mostraram disponíveis para me ajudar, todos eles à sua maneira. Primeiramente gostaria de agradecer à Verónica que tornou todos os infindáveis “Colony PCR” mais divertidos e me ajudou a seguir em frente quando tudo corria mal. À Sara cuja paciente infinitiva em me ensinar a trabalhar na cultura e grande parte das outras técnicas que utilizei neste trabalho, para além de responder sempre com boa disposição a todas as minhas dúvidas e questões que foram enumeras e muitas delas sem nexo, por vezes. À Madalena e aos seus maravilhosos cadernos de laboratório, sem dúvida a minha fonte de inspiração, mesmo longe esteve sempre disponível para responder às minhas dúvidas por mais chatas e aborrecidas que fossem e me fez crer desde o primeiro dia que seria possível.
    [Show full text]
  • Supplemental Table 1 List of Genes Differentially Expressed In
    Supplemental Table 1 List of genes differentially expressed in normal nasopharyngeal epithelium (N), metaplastic and displastic lesions (R), and carcinoma (T). Parametric Permutation Geom Geom Geom Unique Description Clone UG Gene symbol Map p-value p-value mean mean mean id cluster of of of ratios ratios ratios in in in class class class 1 : N 2 : R 3 : T 1 p < 1e-07 0 0.061 0.123 2.708 169329 secretory leukocyte protease IncytePD:2510171 Hs.251754 SLPI 20q12 inhibitor (antileukoproteinase) 2 p < 1e-07 0 0.125 0.394 1.863 163628 sodium channel, nonvoltage-gated IncytePD:1453049 Hs.446415 SCNN1A 12p13 1 alpha 3 p < 1e-07 0 0.122 0.046 1.497 160401 carcinoembryonic antigen-related IncytePD:2060355 Hs.73848 CEACAM6 19q13.2 cell adhesion molecule 6 (non- specific cross reacting antigen) 4 p < 1e-07 0 0.675 1.64 5.594 165101 monoglyceride lipase IncytePD:2174920 Hs.6721 MGLL 3q21.3 5 p < 1e-07 0 0.182 0.487 0.998 166827 nei endonuclease VIII-like 1 (E. IncytePD:1926409 Hs.28355 NEIL1 15q22.33 coli) 6 p < 1e-07 0 0.194 0.339 0.915 162931 hypothetical protein FLJ22418 IncytePD:2816379 Hs.36563 FLJ22418 1p11.1 7 p < 1e-07 0 1.313 0.645 13.593 162399 S100 calcium binding protein P IncytePD:2060823 Hs.2962 S100P 4p16 8 p < 1e-07 0 0.157 1.445 2.563 169315 selenium binding protein 1 IncytePD:2591494 Hs.334841 SELENBP1 1q21-q22 9 p < 1e-07 0 0.046 0.738 1.213 160115 prominin-like 1 (mouse) IncytePD:2070568 Hs.112360 PROML1 4p15.33 10 p < 1e-07 0 0.787 2.264 3.013 167294 HRAS-like suppressor 3 IncytePD:1969263 Hs.37189 HRASLS3 11q12.3 11 p < 1e-07 0 0.292 0.539 1.493 168221 Homo sapiens cDNA FLJ13510 IncytePD:64451 Hs.37896 2 fis, clone PLACE1005146.
    [Show full text]